Abstracts Archive - Page 793 of 2425 - ACR Meeting Abstracts

Abstract Number: 011 • 2020 Pediatric Rheumatology Symposium
Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings
Martina Capponi ¹, Denise Pires Marafon ², Flaminia Rivosecchi ¹, Manuela Pardeo², Fabrizio De Benedetti ² and Antonella Insalaco ², ¹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Due to the lack of widely accepted diagnostic criteria or disease biomarkers, chronic non-bacterial osteomyelitis (CNO) remains a diagnosis of exclusion. Whole-body MRI (WB-MRI) has…
Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Ellen Go¹, Simon Eng ², David Cabral ³ and Rae Yeung ¹, ¹The Hospital for Sick Children, Toronto, Canada, ²Toronto, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
Abstract Number: 015 • 2020 Pediatric Rheumatology Symposium
Normal MRI Appearance of Marrow Adjacent to the Sacroiliac Joints in Healthy Children During Development
Roberto Borgia¹, Leandra Woolnough ¹ and Troy Storey ², ¹University of Florida, Gainesville, ²University of Florida, Gainesvillle
Background/Purpose: MRI examination is frequently used to determine the presence of sacroiliitis in patients suspected of having inflammatory arthritis. In children and adolescents, the vascular…
Abstract Number: 016 • 2020 Pediatric Rheumatology Symposium
Genetic Susceptibility Loci for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Syndrome
Kalpana Manthiram¹, Silvia Preite ², Fatma Dedeoglu ³, Selcan Demir ⁴, Seza Ozen ⁵, Kathryn Edwards ⁶, Sivia Lapidus ⁷, Alexander Katz ², Henry Feder ⁸, Maranda Lawton ³, Greg Licameli ³, Peter Wright ⁹, Karyl Barron ², Amanda Ombrello ², Beverly Barham ², Tina Romeo ¹⁰, Anne Jones ¹¹, Hemalatha Srinivasalu ¹², Pamela Mudd ¹², Roberta DeBiasi ¹², Ahmet Gul ¹³, Gary Marshall ¹⁴, Olcay Jones ¹⁵, Yuriy Stepanovskiy ¹⁶, Polly Ferguson ¹⁷, Pamela Schwartzberg ², Elaine Remmers ² and Daniel Kastner ¹⁸, ¹National Institutes of Health, Bethesda, Maryland, ²National Institutes of Health, Bethesda, ³Boston Children's Hospital, Boston, ⁴Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, ⁶Vanderbilt University School of Medicine, Nashville, ⁷The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, ⁸Connecticut Children's Medical Center, Hartford, ⁹Dartmouth-Hitchcock Medical Center, Lebanon, ¹⁰NIH, Bethesda, ¹¹Bethesda, ¹²Children's National Medical Center, Washington, ¹³Istanbul University, Istanbul, Turkey, ¹⁴University of Louisville School of Medicine, Louisville, ¹⁵Walter Reed National Military Medical Center, Bethesda, ¹⁶Shupyk National Medical Academy of Postgraduate Education, Kiev, ¹⁷University of Iowa Carver College of Medicine, Iowa City, ¹⁸National Human Genome Research Institute, Bethesda
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome of childhood. Although familial clustering of the disease…
Abstract Number: 017 • 2020 Pediatric Rheumatology Symposium
MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Sufia Bakshi¹, Malika Waschmann ², Anders Lindstedt ², Emily Rominger ², Robert Colbert ³ and Keith Sikora ⁴, ¹National Institutes of Health, Bethesda, Maryland, ²National Institutes of Health, Bethesda, ³NIH/NIAMS, Bethesda, Maryland, ⁴National Institutes of Health Clinical Center, Bethesda, Maryland
Background/Purpose: MYD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-kB. We previously reported a heterozygous de novo mutation in MYD88 (S222R)…
Abstract Number: 018 • 2020 Pediatric Rheumatology Symposium
Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
Kathleen Baysac¹, Charles Fisher ¹, Hiroto Nakano ¹, Guangping Sun ², Joshua Milner ³ and Michael Ombrello ¹, ¹NIAMS, NIH, Bethesda, ²NIAID, NIH, Bethesda, ³
Background/Purpose: PLCG2-associated antibody deficiency and immune dysregulation (PLAID) and autoinflammatory PLAID (APLAID) are autosomal dominant diseases caused by mutations of PLCG2. APLAID is clinically characterized…
Abstract Number: 019 • 2020 Pediatric Rheumatology Symposium
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang ¹, Remy Cron ¹, Devin Absher ², Prescott Atkinson ¹, W. Winn Chatham ¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, ²HudsonAlpha Institute for Biotechnology, Huntsville
Background/Purpose: Cytokine storm syndromes (CSS), such as macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (HLH), are life threatening conditions that commonly present with unremitting…
Abstract Number: 020 • 2020 Pediatric Rheumatology Symposium
Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies
Tarin Bigley¹ and Wayne Yokoyama ², ¹Washington University in St. Louis, Saint Louis, Missouri, ²Washington University in St. Louis, St Louis, Missouri
Background/Purpose: Murine roseolovirus (MRV) is a recently sequenced beta-herpesvirus that is a natural murine pathogen and is genetically highly related to HHV6 and HHV7. The…
Abstract Number: 021 • 2020 Pediatric Rheumatology Symposium
Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies
Dawn Wahezi ¹, Natalia Vasquez Canizares ², Gabriel Tarshish ² and Megan Colwell², ¹Children's Hospital at Montefiore, Bronx, ²Children's Hospital at Montefiore, new york
Background/Purpose: The presence of myositis specific autoantibodies (MSA) and myositis associated antibodies (MAA) has been associated with specific clinical phenotypes, various organ involvement and disease…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 023 • 2020 Pediatric Rheumatology Symposium
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Suzanne Li¹, Aashka Patel ², Elena Pope ³, Thomas Mason ⁴, Vidya Sivaraman ⁵, Fatma Dedeoglu ⁶, Kathryn Torok ⁷, Katie Stewart ⁸, Gloria Higgins ⁹, C. Egla Rabinovich ¹⁰, Robert Fuhlbrigge ¹¹, Maria Ibarra ¹², Sandy Hong ¹³, Polly Ferguson ¹⁴, Mara Becker ¹⁵, Brian Feldman ¹⁶ and Ronald Laxer ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Hackensack University Medical Center, Hackensack, ³Hospital For Sick Kids, Toronto, Canada, ⁴Rochester, ⁵Division of Rheumatology, Nationwide Children's Hospital, Bexley, ⁶Boston Children's Hospital, Boston, ⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁸UT Southwestern, Dallas, ⁹Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁰Duke University Hospital, Durham, ¹¹University of Colorado, Aurora, ¹²Children's Mercy Kansas City, Kansas City, ¹³University of Iowa Stead Family Children's Hospital, Iowa City, ¹⁴University of Iowa Carver College of Medicine, Iowa City, ¹⁵Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ¹⁶The Hospital for Sick Children, Toronto, Canada, ¹⁷The Hospital for Sick Children and University of Toronto, Toronto, Canada
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in…
Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 025 • 2020 Pediatric Rheumatology Symposium
HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma
Christina Schutt¹, Emily Mirizio ², Kaila Schollaert-Fitch ² and Kathryn Torok ², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue that is characterized by an earlier inflammatory infiltrate, followed by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].